TMDX vs. MASI, ITGR, LIVN, CNMD, INMD, SLNO, BLFS, ZYXI, AXGN, and EDAP
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Masimo (MASI), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Zynex (ZYXI), AxoGen (AXGN), and Edap Tms (EDAP). These companies are all part of the "electromedical equipment" industry.
TransMedics Group (NASDAQ:TMDX) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Masimo received 366 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 54.78% of users gave TransMedics Group an outperform vote.
TransMedics Group currently has a consensus price target of $119.00, indicating a potential downside of 12.76%. Masimo has a consensus price target of $138.71, indicating a potential upside of 11.42%. Given Masimo's higher possible upside, analysts plainly believe Masimo is more favorable than TransMedics Group.
Masimo has a net margin of 4.01% compared to TransMedics Group's net margin of -3.43%. Masimo's return on equity of 13.26% beat TransMedics Group's return on equity.
TransMedics Group has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
In the previous week, Masimo had 9 more articles in the media than TransMedics Group. MarketBeat recorded 18 mentions for Masimo and 9 mentions for TransMedics Group. Masimo's average media sentiment score of 0.46 beat TransMedics Group's score of 0.43 indicating that Masimo is being referred to more favorably in the news media.
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 7.0% of TransMedics Group shares are held by company insiders. Comparatively, 9.7% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Masimo has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Summary
Masimo beats TransMedics Group on 13 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
